Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, PI3K/AKT/mTOR signaling in cancer, Cancer-related Molecular Pathways, and Immune Cell Function and Interaction.
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib
Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors